TY - JOUR
T1 - Pharmacokinetic properties of benzodiazepine hypnotics
AU - Greenblatt, David J.
AU - Abernethy, Darrell R.
AU - Divoll, Marcia
AU - Harmatz, Jerold S.
AU - Shader, Richard I.
PY - 1983/4
Y1 - 1983/4
N2 - The kinetic properties of three benzodiazepine hypnotics are reviewed. Flurazepam serves as a precursor for at least two rapidly appearing and rapidly cleared metabolites that may contribute to sleep induction and are nonaccumulating. The final metabolite of flurazepam (N-desalkylflurazepam), however, has a long half-life and accumulates during repeated dosage. Temazepam has a relatively slow rate of absorption and an intermediate half-life in the range of 10 to 20 hours. Triazolam has an intermediate rate of absorption; due to its ultrashort half-life (1.5 to 5 hours), triazolam is a nonaccumulating hypnotic. Taken together with sleep laboratory studies and clinical trials, knowledge of the kinetic profile of benzodiazepine hypnotics can assist in evaluating their clinical benefits and disadvantages.
AB - The kinetic properties of three benzodiazepine hypnotics are reviewed. Flurazepam serves as a precursor for at least two rapidly appearing and rapidly cleared metabolites that may contribute to sleep induction and are nonaccumulating. The final metabolite of flurazepam (N-desalkylflurazepam), however, has a long half-life and accumulates during repeated dosage. Temazepam has a relatively slow rate of absorption and an intermediate half-life in the range of 10 to 20 hours. Triazolam has an intermediate rate of absorption; due to its ultrashort half-life (1.5 to 5 hours), triazolam is a nonaccumulating hypnotic. Taken together with sleep laboratory studies and clinical trials, knowledge of the kinetic profile of benzodiazepine hypnotics can assist in evaluating their clinical benefits and disadvantages.
UR - http://www.scopus.com/inward/record.url?scp=0020529904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020529904&partnerID=8YFLogxK
U2 - 10.1097/00004714-198304000-00036
DO - 10.1097/00004714-198304000-00036
M3 - Article
C2 - 6132931
AN - SCOPUS:0020529904
SN - 0271-0749
VL - 3
SP - 129
EP - 132
JO - Journal of clinical psychopharmacology
JF - Journal of clinical psychopharmacology
IS - 2
ER -